Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2019

View Archived Issues

Broken BBB exposes targeting mechanism

Early in ALS/FTD, there's targetable toxicity

FLX Bio presents a novel CCR4 antagonist for the treatment of allergic disorders

APD-588 inhibits inflammation and airway hyperresponsiveness in model of allergic asthma

Urine circulating cell-free DNA as biomarker in renal cell carcinoma

Model suggests gut bacteria cause absorptive hypercalciuria

Polymorphisms in RAGE gene as biomarkers of survival in urothelial cell carcinoma

Combination vaccination enhances influenza-specific immunity

Sustained efficacy seen with zilucoplan in phase II study in patients with myasthenia gravis

Allergan presents phase III results from ACHIEVE II study of ubrogepant for treating migraine

CureVac announces sponsored research agreement for mRNA-based eye therapy candidates

FXR agonists with sustained activity exhibit efficacy in mouse models of colitis

FDA approves Nayzilam to treat intermittent, stereotypic episodes of frequent seizure activity

Bristol-Myers Squibb presents new NR1H4 agonists

Samumed patents DYRK1A and/or GSK-3beta inhibitors

Phase III fliGHt trial provides new safety data on TransCon Growth Hormone in pediatric patients

French researchers disclose BRD4 and MYC inhibitors

Ocular Therapeutics reports topline results from phase III trial of OTX-TP for glaucoma

Kazia collaborates with Alliance to study GDC-0084 in brain metastases

AiCuris synthesizes new HBV inhibitors

Viva Vision Shanghai discloses cell adhesion inhibitory compounds

Phase III KEYNOTE-119 trial of Keyruda in metastatic TNBC fails to meet primary endpoint

New German study investigates adrecizumab for cardiogenic shock

Enrollment opens in new phase IIa study of CC-31244 for ultra-short treatment of hepatitis C

Oncopeptides begins NDA preparations for melflufen in triple-class refractory multiple myeloma

Phase III APeX-2 trial of BCX-7353 to prevent HAE attacks meets primary endpoint